vs
STANDARD BIOTOOLS INC.（LAB）与NEXPOINT DIVERSIFIED REAL ESTATE TRUST（NXDT）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是NEXPOINT DIVERSIFIED REAL ESTATE TRUST的1.1倍（$19.6M vs $18.4M），STANDARD BIOTOOLS INC.净利率更高（-177.4% vs -193.1%，领先15.7%），STANDARD BIOTOOLS INC.同比增速更快（-11.5% vs -29.0%），过去两年NEXPOINT DIVERSIFIED REAL ESTATE TRUST的营收复合增速更高（19.9% vs -12.2%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
NexPoint多元化房地产信托是一家美国上市房地产投资信托，专注于收购、运营和优化覆盖多户住宅、工业物业、办公楼及社区零售空间的多元资产组合，通过租金收入和长期资产增值为投资者创造回报。
LAB vs NXDT — 直观对比
营收规模更大
LAB
是对方的1.1倍
$18.4M
营收增速更快
LAB
高出17.6%
-29.0%
净利率更高
LAB
高出15.7%
-193.1%
两年增速更快
NXDT
近两年复合增速
-12.2%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $18.4M |
| 净利润 | $-34.7M | $-35.5M |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | -18.8% |
| 净利率 | -177.4% | -193.1% |
| 营收同比 | -11.5% | -29.0% |
| 净利润同比 | -28.8% | -291.1% |
| 每股收益（稀释后） | $-0.09 | $-0.73 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABNXDT
| Q4 25 | — | $18.4M | ||
| Q3 25 | $19.6M | $17.5M | ||
| Q2 25 | $21.8M | $21.0M | ||
| Q1 25 | $40.8M | $29.1M | ||
| Q4 24 | — | $25.9M | ||
| Q3 24 | $22.1M | $22.2M | ||
| Q2 24 | $22.5M | $22.3M | ||
| Q1 24 | $45.5M | $12.8M |
净利润LABNXDT
| Q4 25 | — | $-35.5M | ||
| Q3 25 | $-34.7M | $-13.7M | ||
| Q2 25 | $-33.5M | $-45.3M | ||
| Q1 25 | $-26.0M | $-34.3M | ||
| Q4 24 | — | $-9.1M | ||
| Q3 24 | $-26.9M | $-10.0M | ||
| Q2 24 | $-45.7M | $-9.8M | ||
| Q1 24 | $-32.2M | $-22.7M |
毛利率LABNXDT
| Q4 25 | — | — | ||
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — |
营业利润率LABNXDT
| Q4 25 | — | -18.8% | ||
| Q3 25 | -168.5% | -19.1% | ||
| Q2 25 | -118.1% | -0.6% | ||
| Q1 25 | -80.8% | 19.0% | ||
| Q4 24 | — | 3.6% | ||
| Q3 24 | -120.9% | -26.8% | ||
| Q2 24 | -134.5% | 2.7% | ||
| Q1 24 | -132.2% | 2.1% |
净利率LABNXDT
| Q4 25 | — | -193.1% | ||
| Q3 25 | -177.4% | -78.4% | ||
| Q2 25 | -153.7% | -215.1% | ||
| Q1 25 | -63.8% | -118.0% | ||
| Q4 24 | — | -35.0% | ||
| Q3 24 | -122.0% | -45.2% | ||
| Q2 24 | -203.3% | -43.9% | ||
| Q1 24 | -70.6% | -177.3% |
每股收益（稀释后）LABNXDT
| Q4 25 | — | $-0.73 | ||
| Q3 25 | $-0.09 | $-0.29 | ||
| Q2 25 | $-0.09 | $-0.99 | ||
| Q1 25 | $-0.07 | $-0.80 | ||
| Q4 24 | — | $-0.20 | ||
| Q3 24 | $-0.07 | $-0.25 | ||
| Q2 24 | $-0.12 | $-0.24 | ||
| Q1 24 | $-0.27 | $-0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $8.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $700.1M |
| 总资产 | $539.6M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABNXDT
| Q4 25 | — | $8.2M | ||
| Q3 25 | $129.4M | $5.3M | ||
| Q2 25 | $158.6M | $4.7M | ||
| Q1 25 | $150.9M | $9.5M | ||
| Q4 24 | — | $8.8M | ||
| Q3 24 | $210.6M | $8.5M | ||
| Q2 24 | $269.8M | $28.4M | ||
| Q1 24 | $287.1M | $20.2M |
总债务LABNXDT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $55.2M | — | ||
| Q2 24 | $55.1M | — | ||
| Q1 24 | $55.0M | — |
股东权益LABNXDT
| Q4 25 | — | $700.1M | ||
| Q3 25 | $399.7M | $739.0M | ||
| Q2 25 | $424.5M | $752.7M | ||
| Q1 25 | $454.6M | $802.7M | ||
| Q4 24 | — | $836.5M | ||
| Q3 24 | $489.3M | $842.9M | ||
| Q2 24 | $510.3M | $859.1M | ||
| Q1 24 | $577.3M | $863.0M |
总资产LABNXDT
| Q4 25 | — | $1.1B | ||
| Q3 25 | $539.6M | $1.1B | ||
| Q2 25 | $557.0M | $1.1B | ||
| Q1 25 | $579.6M | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $681.5M | $1.2B | ||
| Q2 24 | $708.7M | $1.2B | ||
| Q1 24 | $777.7M | $1.1B |
负债/权益比LABNXDT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.11× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $9.2M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | — |
| 自由现金流率自由现金流/营收 | -118.1% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-111.1M | — |
8季度趋势，按日历期对齐
经营现金流LABNXDT
| Q4 25 | — | $9.2M | ||
| Q3 25 | $-22.2M | $835.0K | ||
| Q2 25 | $-20.7M | $75.0K | ||
| Q1 25 | $-30.3M | $7.1M | ||
| Q4 24 | — | $-11.7M | ||
| Q3 24 | $-27.9M | $497.0K | ||
| Q2 24 | $-39.0M | $-5.5M | ||
| Q1 24 | $-62.5M | $-2.6M |
自由现金流LABNXDT
| Q4 25 | — | — | ||
| Q3 25 | $-23.1M | — | ||
| Q2 25 | $-22.6M | — | ||
| Q1 25 | $-35.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-30.1M | — | ||
| Q2 24 | $-41.0M | — | ||
| Q1 24 | $-63.3M | — |
自由现金流率LABNXDT
| Q4 25 | — | — | ||
| Q3 25 | -118.1% | — | ||
| Q2 25 | -103.6% | — | ||
| Q1 25 | -86.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -136.4% | — | ||
| Q2 24 | -182.2% | — | ||
| Q1 24 | -138.9% | — |
资本支出强度LABNXDT
| Q4 25 | — | — | ||
| Q3 25 | 4.5% | — | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 12.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | 1.7% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
NXDT
暂无分部数据
